Anjali S. Advani
About
Anjali S. Advani is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics.
According to data from OpenAlex, Anjali S. Advani has authored 298 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 205 papers in Hematology, 135 papers in Public Health, Environmental and Occupational Health and 87 papers in Genetics. Recurrent topics in Anjali S. Advani's work include Acute Myeloid Leukemia Research (161 papers), Acute Lymphoblastic Leukemia research (131 papers) and Chronic Myeloid Leukemia Treatments (68 papers). Anjali S. Advani is often cited by papers focused on Acute Myeloid Leukemia Research (161 papers), Acute Lymphoblastic Leukemia research (131 papers) and Chronic Myeloid Leukemia Treatments (68 papers). Anjali S. Advani collaborates with scholars based in United States, Germany and United Kingdom. Anjali S. Advani's co-authors include Daniel J. DeAngelo, Hagop M. Kantarjian, Mikkael A. Sekeres, Wendy Stock, Erik Vandendries, Michaela Liedtke, Matthias Stelljes, Susan O’Brien, Nicola Gökbuget and Barbara Sleight and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Anjali S. Advani
285 papers receiving 6.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Anjali S. Advani United States | 41 | 3.5k | 3.0k | 2.9k | 1.6k | 1.2k | 298 | 7.1k | ||
| Joseph Brandwein Canada | 40 | 2.7k 0.8× | 1.2k 0.4× | 1.8k 0.6× | 1.8k 1.1× | 1.0k 0.8× | 191 | 5.3k | ||
| Peter F. Coccia United States | 44 | 1.7k 0.5× | 1.7k 0.6× | 1.5k 0.5× | 1.3k 0.8× | 956 0.8× | 108 | 5.7k | ||
| Andrew McMillan United Kingdom | 32 | 1.9k 0.5× | 2.2k 0.7× | 2.4k 0.8× | 388 0.2× | 944 0.8× | 117 | 5.5k | ||
| F R Appelbaum United States | 47 | 6.0k 1.7× | 1.3k 0.4× | 2.9k 1.0× | 847 0.5× | 1.2k 1.0× | 99 | 8.5k | ||
| Elizabeth A. Raetz United States | 48 | 2.9k 0.8× | 5.4k 1.8× | 2.2k 0.8× | 1.6k 1.0× | 547 0.5× | 245 | 7.7k | ||
| Bernhard Wörmann Germany | 40 | 3.3k 0.9× | 1.2k 0.4× | 1.9k 0.7× | 1.9k 1.2× | 1.5k 1.3× | 173 | 6.3k | ||
| D Maraninchi France | 47 | 3.7k 1.0× | 1.1k 0.4× | 3.8k 1.3× | 1.3k 0.8× | 1.0k 0.9× | 259 | 8.5k | ||
| Fabrizio Pane Italy | 42 | 6.7k 1.9× | 1.6k 0.5× | 1.3k 0.5× | 1.9k 1.2× | 4.9k 4.0× | 289 | 9.4k | ||
| Françoise Huguet France | 39 | 5.6k 1.6× | 2.7k 0.9× | 1.7k 0.6× | 1.2k 0.8× | 3.2k 2.7× | 179 | 8.0k | ||
| Roy B. Jones United States | 43 | 3.4k 1.0× | 880 0.3× | 2.5k 0.9× | 970 0.6× | 1.2k 1.0× | 176 | 6.6k |
Countries citing papers authored by Anjali S. Advani
Since
Specialization
Citations
This map shows the geographic impact of Anjali S. Advani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anjali S. Advani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anjali S. Advani more than expected).
Fields of papers citing papers by Anjali S. Advani
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Anjali S. Advani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anjali S. Advani. The network helps show where Anjali S. Advani may publish in the future.
Co-authorship network of co-authors of Anjali S. Advani
This figure shows the co-authorship network connecting the top 25 collaborators of Anjali S. Advani. A scholar is included among the top collaborators of Anjali S. Advani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anjali S. Advani. Anjali S. Advani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Daver, Naval, Pau Montesinos, Jessica K. Altman, et al.. (2024). A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.. Journal of Clinical Oncology. 42(16_suppl). TPS6585–TPS6585.
2.
Grieselhuber, Nicole R., Anjali S. Advani, Abdulraheem Yacoub, et al.. (2024). PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study. Blood. 144(Supplement 1). 1840–1840.
3.
Mukherjee, Sudipto, Weichuan Dong, Nicholas K. Schiltz, et al.. (2023). Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes. The Oncologist. 28(10). 901–910.
4.
Kantarjian, Hagop M., Wendy Stock, Ryan D. Cassaday, et al.. (2021). Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clinical Cancer Research. 27(10). 2742–2754.
5.
Advani, Anjali S., Anna Moseley, Kristen M. O’Dwyer, et al.. (2021). A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations). Blood. 138(Supplement 1). 3397–3397.
6.
Advani, Anjali S. & Rabi Hanna. (2019). The treatment of adolescents and young adults with acute lymphoblastic leukemia. Leukemia & lymphoma. 61(1). 18–26.
7.
Madanat, Yazan F., Mikkael A. Sekeres, Sudipto Mukherjee, et al.. (2018). Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes. Blood. 132(Supplement 1). 1797–1797.
8.
Advani, Anjali S., Elias Jabbour, Matthias Stelljes, et al.. (2017). Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status. Blood. 130. 2557–2557.
9.
Abuhadra, Nour, Sudipto Mukherjee, Cassandra M. Hirsch, et al.. (2017). BCOR Mutations in Myelodysplastic Syndromes (MDS): Mutation Characteristics Impact Clinical Outcomes. Blood. 130. 5304–5304.
10.
Madanat, Yazan F., Tomas Radivoyevitch, Aziz Nazha, et al.. (2017). Mutational Signatures Associated with Intensity and Duration of Smoking in Myelodysplastic Syndromes (MDS). Blood. 130. 424–424.
11.
Nazha, Aziz, Sudipto Mukherjee, Vera Ademà, et al.. (2017). A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML). Blood. 130. 1408–1408.
12.
Kantarjian, Hagop M., Daniel J. DeAngelo, Matthias Stelljes, et al.. (2017). Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study. Blood. 130. 2574–2574.
13.
Madanat, Yazan F., Sudipto Mukherjee, Cassandra M. Hirsch, et al.. (2017). Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS). Blood. 130. 2972–2972.
14.
Ahmed, Hina, Sagar S. Patel, Bhumika Patel, et al.. (2017). Predictors for Recurrent 30-Day Unplanned Readmissions in Patients with Hematologic Malignancies. Blood. 130. 532–532.
15.
Ebrahem, Quteba, Reda Z. Mahfouz, Lisa Durkin, et al.. (2015). Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response. Blood. 126(23). 678–678.
16.
Fayad, Luis, Fritz Offner, Mitchell R. Smith, et al.. (2013). Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. Journal of Clinical Oncology. 31(5). 573–583.
17.
Sidana, Surbhi, Sudipto Mukherjee, Paul Elson, et al.. (2013). The Degree and Effect Of Weight Loss In Acute Myeloid Leukemia Patients Receiving Induction and Post-Remission Chemotherapy. Blood. 122(21). 3889–3889.
18.
Mohan, Sanjay & Anjali S. Advani. (2011). Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Journal of Adolescent and Young Adult Oncology. 1(1). 19–24.
19.
Advani, Anjali S., Bertrand Coiffier, Myron S. Czuczman, et al.. (2010). Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. Journal of Clinical Oncology. 28(12). 2085–2093.
20.
Sekeres, Mikkael A., Paul Elson, Matt Kalaycio, et al.. (2008). Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 113(1). 28–36.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Joseph Brandwein Breakdown of academic impact, for papers by Peter F. Coccia Breakdown of academic impact, for papers by Andrew McMillan Breakdown of academic impact, for papers by F R Appelbaum Breakdown of academic impact, for papers by Elizabeth A. Raetz Breakdown of academic impact, for papers by Bernhard Wörmann Breakdown of academic impact, for papers by D Maraninchi Breakdown of academic impact, for papers by Fabrizio Pane Breakdown of academic impact, for papers by Françoise Huguet Breakdown of academic impact, for papers by Roy B. Jones